Loading company…
Syneron uses AI to research and develop synthetic peptide drugs.
Syneron researches and develops synthetic peptide drugs using its SynCore platform, which applies AI to drug design, screening, synthesis, characterization, and optimization. Its work also covers enzyme engineering. Founded in 2022, the company is based in Guangzhou, China. In November 2024, it closed Series A funding to accelerate peptide drug development.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in